Μετάβαση στο κύριο περιεχόμενο

! # Ola via Alexandros G.Sfakianakis on Inoreader

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Invest New Drugs. 2017 Dec 01;:

Authors: Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A

Abstract
Background The signaling protein p38 mitogen-activated protein kinase (MAPK) regulates the tumor cell microenvironment, modulating cell survival, migration, and invasion. This phase 1 study evaluated the safety of p38 MAPK inhibitor LY3007113 in patients with advanced cancer to establish a recommended phase 2 dose. Methods In part A (dose escalation), LY3007113 was administered orally every 12 h (Q12H) at doses ranging from 20 mg to 200 mg daily on a 28-day cycle until the maximum tolerated dose (MTD) was reached. In part B (dose confirmation), patients received MTD. Safety, pharmacokinetics, pharmacodynamics, and tumor response data were evaluated. Results MTD was 30 mg Q12H. The most frequent treatment-related adverse events (>10%) were tremor, rash, stomatitis, increased blood creatine phosphokinase, and fatigue. Grade ≥ 3 treatment-related adverse events included upper gastrointestinal haemorrhage and increased hepatic enzyme, both occurring at 40 mg Q12H and considered dose-limiting toxicities. LY3007113 exhibited an approximately dose-proportional increase in exposure and time-independent pharmacokinetics after repeated dosing. Maximal inhibition (80%) of primary biomarker MAPK-activated protein kinase 2 in peripheral blood mononuclear cells was not reached, and sustained minimal inhibition (60%) was not maintained for 6 h after dosing to achieve a biologically effective dose (BED). The best overall response in part B was stable disease in 3 of 27 patients. Conclusions The recommended phase 2 dosage of LY3007113 was 30 mg Q12H. Three patients continued treatment after the first radiographic assessment, and the BED was not achieved. Further clinical development of this compound is not planned as toxicity precluded achieving a biologically effective dose.

PMID: 29196957 [PubMed - as supplied by publisher]



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2ntLdTm
via IFTTT

Σχόλια

Δημοφιλείς αναρτήσεις από αυτό το ιστολόγιο

Does CBD Oil Lower Blood Pressure?

Does CBD Oil Lower Blood Pressure?This article was originally published at SundayScaries."
Madeline TaylorPOSTED ONJanuary 13, 2019 High blood pressure is a serious condition that currently affects thousands of adults in America. Statistics show that 33% of adults who are above the age of 20 struggle with high blood pressure and that figure reaches a whopping 66% for those in their mid-60 and over. It goes without saying that high blood pressure is becoming a nasty rising trend, which is only going to worsen if changes to the system aren't made. While there is already a substantial amount of research into hypertension, a succinct cure is yet to be found. And, thanks to the rise of natural medicines, including medical marijuana, many people now suspect that cannabis-based products could provide the answers we have been looking for with regards to lowering blood pressure in modern society.Hypertension doesn't immediately strike us as a fatal condition when you compare it to a…

Accessory Auricles: Systematic Review of Definition, Associated Conditions, and Recommendations for Clinical Practice

Abstract Accessory auricles are rare congenital abnormalities embryologically derived from the first branchial arch. Presentation may be variable with locations grouped into anatomical zones based on the frequency of location found in the literature. This study reviewed the papers between 1981 and 2017. Findings included an association with syndromes including Goldenhar, VACTERL, Treacher–Collins, Townes–Brocks, and Wolf–Hirschhorn. Based on histological and embryological evidence, the term "accessory auricle" is best used as an umbrella term to define this difference. Finally, indications are provided for imaging and laboratory investigations to guide the physician treating patients with accessory auricles. Address correspondence and reprint requests to Mark S. Lloyd, MPhil, FRCS(Plast), Department of Plastic Surgery, Autologous Ear Reconstruction Service, Birmingham Children's and Women's Hospital NHS Trust, 4th Floor, Ladywood House, Steelhouse Lane, Birmingham B4…

Efficacy and Tolerability of CyberKnife Stereotactic Robotic Radiotherapy for Primary or Secondary Orbital Lesions: A Single-Center Retrospective Experience

Technology in Cancer Research &Treatment, Volume 18, Issue , January 2019.


from A via a.sfakia on Inoreader http://bit.ly/2Qfe0Ek